Skip to main content
Premium Trial:

Request an Annual Quote

Symyx Board Rejects Certara Bid, Favors Accelrys Deal

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Bioinformatics firm Symyx Technologies today said that its board of directors has determined that a bid from Certara to acquire the firm for $5.75 per share in cash does not represent a superior offer to an earlier bid from Accelrys.

In April, Accelrys had offered to merge with Symyx in a deal valued at around $175 million, or around $5 per share for each share of Symyx. As reported by GenomeWeb Daily News sister publication BioInform, Certara had initially entered a competing bid of $6.75 per share, but last week it, and its private equity backer Vector Capital, lowered the bid to $5.75, valuing Symyx at around $200 million.

Among the reasons why Symyx's board favors the Accelrys proposal is that Symyx shareholders would own 50 percent of the combined firm, which it said would provide a greater upside. Symyx also said that Certara's offer does not provide "sufficient certainty to closure necessary to protect Symyx stockholders."

Symyx said that its board also has reaffirmed its commitment to support the definitive merger agreement with Accelrys.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.